Beyond Weight Loss: Semaglutide Shows Potential to Rebuild Arthritic Cartilage

Emerging research suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may do more than just lighten the mechanical load on joints. A breakthrough study published in Cell Metabolism in February 2026 indicates that the drug could actively stimulate cartilage growth and reduce inflammation in patients with knee osteoarthritis. This discovery marks a significant shift in orthopedic medicine, moving from symptom management to potential tissue regeneration.

By: AXL Media

Published: Feb 21, 2026, 3:49 AM EST

Source: Information for this report was sourced from Science News - https://www.sciencenews.org/article/ozempic-osteoarthritis-arthritis-semaglutide

Evidence of Cartilage Regeneration

In a pioneering study involving both mice and human participants, researchers discovered that semaglutide treatment led to a measurable increase in the thickness of knee cartilage. While weight loss is a known benefit for joint health, this study utilized a control group of "drug-free" mice with restricted food intake to match the weight loss of the treated group. Only the mice receiving semaglutide showed improved joint health and less cartilage breakdown. In a small clinical trial accompanying the research, human participants saw a 17% increase in cartilage thickness after six months of treatment, as verified by MRI scans.

The Metabolic Fueling Mechanism

The study suggests that semaglutide’s impact on joints is driven by a cellular metabolic shift rather than just reduced physical pressure. Researchers found that the drug scales up energy production, specifically ATP, within the cartilage cells. This increase in cellular "fuel" appears to enable the tissue to repair and maintain itself more effectively. This biological precision suggests that GLP-1 receptor agonists may have systemwide regenerative benefits that extend far beyond glucose regulation and appetite suppression.

Clinical Impact on Pain and Mobility

The therapeutic potential of semaglutide was further underscored by the STEP 9 clinical trial, which involved 407 adults with obesity and knee osteoarthritis. Over a 68-week period, participants receiving a weekly 2.4 mg dose of semaglutide reported a 41.7-point drop in pain scores on a 100-point scale, compared to a 27.5-point drop in the placebo group. Beyond pain relief, treated individuals nearly doubled their improvement in physical function and mobility, suggesting the drug could significantly delay or even prevent the need for total knee replacement surgeries.